Why the application of IVIG might be beneficial in patients with COVID-19 – Authors' reply

Detalles Bibliográficos
Autores principales: Mazeraud, Aurélien, Wolff, Michel, Lucas, Bruno, Sharshar, Tarek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806197/
https://www.ncbi.nlm.nih.gov/pubmed/35120612
http://dx.doi.org/10.1016/S2213-2600(21)00550-6
_version_ 1784643388746760192
author Mazeraud, Aurélien
Wolff, Michel
Lucas, Bruno
Sharshar, Tarek
author_facet Mazeraud, Aurélien
Wolff, Michel
Lucas, Bruno
Sharshar, Tarek
author_sort Mazeraud, Aurélien
collection PubMed
description
format Online
Article
Text
id pubmed-8806197
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-88061972022-02-02 Why the application of IVIG might be beneficial in patients with COVID-19 – Authors' reply Mazeraud, Aurélien Wolff, Michel Lucas, Bruno Sharshar, Tarek Lancet Respir Med Correspondence Elsevier Ltd. 2022-02 2022-02-01 /pmc/articles/PMC8806197/ /pubmed/35120612 http://dx.doi.org/10.1016/S2213-2600(21)00550-6 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Correspondence
Mazeraud, Aurélien
Wolff, Michel
Lucas, Bruno
Sharshar, Tarek
Why the application of IVIG might be beneficial in patients with COVID-19 – Authors' reply
title Why the application of IVIG might be beneficial in patients with COVID-19 – Authors' reply
title_full Why the application of IVIG might be beneficial in patients with COVID-19 – Authors' reply
title_fullStr Why the application of IVIG might be beneficial in patients with COVID-19 – Authors' reply
title_full_unstemmed Why the application of IVIG might be beneficial in patients with COVID-19 – Authors' reply
title_short Why the application of IVIG might be beneficial in patients with COVID-19 – Authors' reply
title_sort why the application of ivig might be beneficial in patients with covid-19 – authors' reply
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8806197/
https://www.ncbi.nlm.nih.gov/pubmed/35120612
http://dx.doi.org/10.1016/S2213-2600(21)00550-6
work_keys_str_mv AT mazeraudaurelien whytheapplicationofivigmightbebeneficialinpatientswithcovid19authorsreply
AT wolffmichel whytheapplicationofivigmightbebeneficialinpatientswithcovid19authorsreply
AT lucasbruno whytheapplicationofivigmightbebeneficialinpatientswithcovid19authorsreply
AT sharshartarek whytheapplicationofivigmightbebeneficialinpatientswithcovid19authorsreply

Ejemplares similares